| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02704962 | Schizophrenia | Drug: full-dose olanzapine | Kaohsiung Kai-Suan Psychiatric Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan) | Phase 4 | 2012-01-01 | 2016-03-04 |
| NCT01765829 | Psychosis Nos/Other | Drug: Discontinuation antipsychotic treatment|Drug: Antipsychotic treatment | Fundacin Pblica Andaluza Progreso y Salud|Instituto de Salud Carlos III|Andalusian Initiative for Advanced Therapies - Fundacin Pblica Andaluza Progreso y Salud | Phase 3 | 2012-11-01 | 2014-12-04 |
| NCT02582736 | Psychotic Disorders|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Diabetes Mellitus, Type 2 | Drug: Olanzapine|Drug: Risperidone|Drug: atypical antipsychotics (other)|Drug: typical antipsychotics | Canadian Network for Observational Drug Effect Studies, CNODES|Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR) | 2012-04-01 | 2015-10-20 |
| NCT01231074 | Obesity|Weight Gain|Psychotropic Induced Weight Gain | Drug: Metformin | Nationwide Children's Hospital | Phase 1 | 2010-02-01 | 2010-10-29 |
| NCT02600741 | Schizophrenia | Other: Caregiver psycho-education and skills training|Other: Caregiver support available at the study site|Drug: Paliperidone palmitate|Drug: Chlorpromazine|Drug: Droperidol|Drug: Fluphenazine|Drug: Haloperidol|Drug: Loxapine|Drug: Perphenazine|Drug: Pimozide|Drug: Prochlorperazine|Drug: Thiothixene|Drug: Thioridazine|Drug: Trifluoperazine|Drug: Aripiprazole|Drug: Asenapine|Drug: Clozapine|Drug: Iloperidone|Drug: Olanzapine|Drug: Paliperidone|Drug: Quetiapine|Drug: Risperidone|Drug: Ziprasidone | Janssen Scientific Affairs, LLC | | 2015-07-24 | 2017-03-17 |
